Affinity Asset Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Affinity Asset Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.7M	Buy	562,631 +12,631	+2%	+$519K	1.53%	18
2025 Q4	$22.2M	Buy	+550,000	New	+$12.7M	1.27%	25
2024 Q4	–	Sell	-600,000	Closed	-$5M	–	100
2024 Q3	$5M	Buy	+600,000	New	+$4.94M	0.68%	43
2024 Q2	–	Sell	-450,000	Closed	-$2.95M	–	120
2024 Q1	$2.95M	Buy	450,000 +384,000	+582%	+$2.51M	0.37%	66
2023 Q4	$428K	Sell	66,000 -259,000	-80%	-$1.37M	0.08%	76
2023 Q3	$1.63M	Buy	+325,000	New	+$2.06M	0.46%	49
2022 Q3	–	Sell	-401,268	Closed	-$995K	–	80
2022 Q2	$995K	Buy	+401,268	New	+$801K	0.42%	41

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Affinity Asset Advisors's TERN Position: Q1 2026 in Review

Affinity Asset Advisors increased its Terns Pharmaceuticals (TERN) stake by 2.3% in Q1 2026, buying an estimated $519K and bringing the position to 562,631 shares worth $29.7M. The position accounts for 1.53% of the portfolio, ranked #18.

Affinity Asset Advisors first reported a position in TERN in Q2 2022 and has held it in 7 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Affinity Asset Advisors held 562,631 shares of Terns Pharmaceuticals worth $29.7M as of Q1 2026.
Affinity Asset Advisors bought 12,631 Terns Pharmaceuticals shares in Q1 2026, an estimated $519K.
Terns Pharmaceuticals made up 1.53% of Affinity Asset Advisors's portfolio in Q1 2026, its #18 holding.
Affinity Asset Advisors first reported a position in Terns Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.